Results 151 to 160 of about 113,904,810 (178)
International Journal of Molecular Sciences, 2023 The substance P (SP)/neurokinin-1 receptor (NK-1R) system is involved in cancer progression. NK-1R, activated by SP, promotes tumor cell proliferation and migration, angiogenesis, the Warburg effect, and the prevention of apoptosis. Tumor cells overexpress NK-1R, which influences their viability.
Rafael Coveñas +2 more
exaly +4 more sources
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia [PDF]
Journal of Clinical Medicine, 2020 Acute myeloid leukemia (AML) is an incurable hematological malignancy. To treat the disease successfully, new therapeutic strategies are urgently needed. One of these strategies can be the use of neurokinin-1 receptor (NK-1R) antagonists (e.g., aprepitant), because the substance P (SP)/NK-1R system is involved in cancer progression, including AML.
Rafael Coveñas, Miguel Muñoz
exaly +6 more sources
CancersBackground: Diffuse intrinsic pontine glioma (DIPG) is a devastating childhood brainstem tumor. The median survival of DIPG is 16–24 months independent of the treatment received. Therefore, new therapeutic strategies against DIPG are urgently needed. Substance P (SP) peptide, through the neurokinin neurokinin-1 receptor (NK-1R), is involved in glioma ...
Marisa Rosso, Miguel Muñoz
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Review of Anticancer Therapy, 2004
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life, and although the use of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists plus dexamethasone has significantly improved the control of acute CINV, delayed nausea and vomiting remain a significant clinical problem.
Rudolph Navari
exaly +3 more sources
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life, and although the use of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists plus dexamethasone has significantly improved the control of acute CINV, delayed nausea and vomiting remain a significant clinical problem.
Rudolph Navari
exaly +3 more sources
Current Medicinal Chemistry, 2023
Background: Although chemotherapy is predominantly used for cancer treatment, it can be ineffective and can induce serious side effects and lead to chemoresistance. It is essential to discover novel drugs that can enhance the antitumor activity and at the same time, counteract the severe side effects, of chemotherapy. The substance P (SP)/neurokinin-1
Rafael Coveñas +2 more
exaly +3 more sources
Background: Although chemotherapy is predominantly used for cancer treatment, it can be ineffective and can induce serious side effects and lead to chemoresistance. It is essential to discover novel drugs that can enhance the antitumor activity and at the same time, counteract the severe side effects, of chemotherapy. The substance P (SP)/neurokinin-1
Rafael Coveñas +2 more
exaly +3 more sources
Neurokinin-1 Receptor Antagonist (Aprepitant) Suppresses HIV-1 Infection of Microglia/Macrophages [PDF]
Journal of NeuroImmune Pharmacology, 2008 Neurokinin-1 receptor (NK-1R) antagonists suppress HIV-1 infection of macrophages in vitro. We have further investigated the anti-HIV-1 activity of aprepitant, a Food and Drug Administration-approved NK-1R antagonist, and its cytotoxic effect in the macrophage/microglia system. Aprepitant inhibited infection of macrophages with primary HIV-1 R5 strains
Yan-Jian Wang
exaly +3 more sources
Annals of the New York Academy of Sciences, 2011
Chemotherapy can be a life‐prolonging treatment for many cancer patients, but it is often associated with profound nausea and vomiting that is so distressing that patients may delay or decline treatment to avoid these side effects. EMEND™ (aprepitant) is the first and only neurokinin‐1 (NK‐1) receptor antagonist available on the market for the ...
Richard Hargreaves
exaly +3 more sources
Chemotherapy can be a life‐prolonging treatment for many cancer patients, but it is often associated with profound nausea and vomiting that is so distressing that patients may delay or decline treatment to avoid these side effects. EMEND™ (aprepitant) is the first and only neurokinin‐1 (NK‐1) receptor antagonist available on the market for the ...
Richard Hargreaves
exaly +3 more sources
Neurogastroenterology and Motility, 2013
AbstractBackgroundSubstance P (SP) is a member of the neurokinin (NK) family and is one of the established neurotransmitters in the mammalian central and enteric nervous system. It is unclear whetherNK1 receptors are involved in the control of gastric sensorimotor function in man.MethodsWe studied the effects of aprepitant, anNK1 receptor antagonist ...
Jan Tack, F Akyuz, A Pauwels
exaly +3 more sources
AbstractBackgroundSubstance P (SP) is a member of the neurokinin (NK) family and is one of the established neurotransmitters in the mammalian central and enteric nervous system. It is unclear whetherNK1 receptors are involved in the control of gastric sensorimotor function in man.MethodsWe studied the effects of aprepitant, anNK1 receptor antagonist ...
Jan Tack, F Akyuz, A Pauwels
exaly +3 more sources
Molecular Immunology, 2019
Atherosclerosis is the main cause of many cardiovascular diseases. Endothelial dysfunction is recognized as an early event in the development of atherosclerosis. Many drugs have been studied to mitigate hyperlipidemia-induced endothelial injury. Studies have demonstrated that neuropeptide substance P (SP) and its preferred receptor neurokinin receptor ...
Yong Xi, Hongshun Yin
exaly +3 more sources
Atherosclerosis is the main cause of many cardiovascular diseases. Endothelial dysfunction is recognized as an early event in the development of atherosclerosis. Many drugs have been studied to mitigate hyperlipidemia-induced endothelial injury. Studies have demonstrated that neuropeptide substance P (SP) and its preferred receptor neurokinin receptor ...
Yong Xi, Hongshun Yin
exaly +3 more sources
Addition of the Neurokinin 1 Receptor Antagonist Aprepitant to Standard Antiemetic Therapy Improves Control of Chemotherapy-Induced Nausea and Vomiting [PDF]
Cancer, 2003 AbstractBACKGROUNDAprepitant is a novel neurokinin 1 (NK1) antagonist that has been shown to improve control of chemotherapy‐induced nausea and vomiting (CINV) when added to a standard antiemetic regimen of a 5‐hydroxytriptamine‐3 antagonist plus a corticosteroid.
Alexandra D Carides +2 more
exaly +3 more sources